Braveheart Bio hosts investor webinar on cardiac myosin inhibitor program

BRVE•2026-10-30

Braveheart Bio will host an investor and analyst webinar on Nov. 6, 2026, focused on BHB-1893’s clinical development for obstructive and non-obstructive hypertrophic cardiomyopathy.

1. Webinar details

The webinar is scheduled for 4:35 p.m. to 6:05 p.m. ET. Management will be joined by physicians Anjali Owens and Mariko Harper for presentations, followed by a live question-and-answer session.

Braveheart Bio hosts investor webinar on cardiac myosin inhibitor program

1. Webinar details

Related News

StoneX cuts Pinterest target price to $26 from $33

Terawulf Inc.: B. Riley cuts target price to $26.00 from $40.00

Bristol-Myers Squibb announces availability of Form 10-Q for period ended Sept. 30, 2026

Oppenheimer cuts Amazon target price to $285 from $320

B. Riley cuts Core Scientific target price to $31 from $42